The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

被引:0
|
作者
Hlin Kvartsberg
Tammaryn Lashley
Christina E. Murray
Gunnar Brinkmalm
Nicholas C. Cullen
Kina Höglund
Henrik Zetterberg
Kaj Blennow
Erik Portelius
机构
[1] The Sahlgrenska Academy at the University of Gothenburg,Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology
[2] Sahlgrenska University Hospital/Mölndal,Queen Square Brain Bank for Neurological Disorders, Department of Movement Disorders
[3] UCL Institute of Neurology,Department of Neurodegenerative Disease
[4] UCL Institute of Neurology,Clinical Neurochemistry Laboratory
[5] UK Dementia Research Institute at UCL,Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Disease Research, Neurogeriatrics Division
[6] Sahlgrenska University Hospital,undefined
[7] Karolinska Institutet,undefined
来源
Acta Neuropathologica | 2019年 / 137卷
关键词
Neurogranin; Alzheimer’s disease; Brain tissue; Familial Alzheimer’s disease; Mass spectrometry;
D O I
暂无
中图分类号
学科分类号
摘要
Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) is a cerebrospinal fluid (CSF) biomarker for AD, also in the prodromal phase. Here we tested the hypothesis that during AD neurodegeneration, processing of full-length Ng into endogenous peptides in the brain is increased. We characterized Ng in post-mortem brain tissue and investigated the levels of endogenous Ng peptides in relation to full-length protein in brain tissue of patients with sporadic (sAD) and familial Alzheimer’s disease (fAD), healthy controls and individuals who were cognitively unaffected but amyloid-positive (CU-AP) in two different brain regions. Brain tissue from parietal cortex [sAD (n = 10) and age-matched controls (n = 10)] and temporal cortex [sAD (n = 9), fAD (n = 10), CU-AP (n = 13) and controls (n = 9)] were included and all the samples were analyzed by three different methods. Using high-resolution mass spectrometry, 39 endogenous Ng peptides were identified while full-length Ng was found to be modified including disulfide bridges or glutathione. In sAD parietal cortex, the ratio of peptide-to-total full-length Ng was significantly increased for eight endogenous Ng peptides compared to controls. In the temporal cortex, several of the peptide-to-total full-length Ng ratios were increased in both sAD and fAD cases compared to controls and CU-AP. This finding was confirmed by western blot, which mainly detects full-length Ng, and enzyme-linked immunosorbent assay, most likely detecting a mix of peptides and full-length Ng. In addition, Ng was significantly associated with the degree of amyloid and tau pathology. These results suggest that processing of Ng into peptides is increased in AD brain tissue, which may reflect the ongoing synaptic degeneration, and which is also mirrored as increased levels of Ng peptides in CSF.
引用
收藏
页码:89 / 102
页数:13
相关论文
共 50 条
  • [31] Proteases Upregulation in Sporadic Alzheimer's Disease Brain
    Medoro, Alessandro
    Bartollino, Silvia
    Mignogna, Donatella
    Marziliano, Nicola
    Porcile, Carola
    Nizzari, Mario
    Florio, Tullio
    Pagano, Aldo
    Raimo, Gennaro
    Intrieri, Mariano
    Russo, Claudio
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 68 (03) : 931 - 938
  • [32] Association between plasma exosome neurogranin and brain structure in patients with Alzheimer's disease: a protocol study
    He, MengFei
    Sun, Li
    Cao, Wenhui
    Yin, Changhao
    Sun, Wenqiang
    Liu, Ping
    Tan, Lin
    Xu, Zheng
    Zhao, Weina
    BMJ OPEN, 2020, 10 (08): : e036990
  • [33] Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease
    Portelius, Erik
    Bogdanovic, Nenad
    Gustavsson, Mikael K.
    Volkmann, Inga
    Brinkmalm, Gunnar
    Zetterberg, Henrik
    Winblad, Bengt
    Blennow, Kaj
    ACTA NEUROPATHOLOGICA, 2010, 120 (02) : 185 - 193
  • [34] Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease
    Erik Portelius
    Nenad Bogdanovic
    Mikael K. Gustavsson
    Inga Volkmann
    Gunnar Brinkmalm
    Henrik Zetterberg
    Bengt Winblad
    Kaj Blennow
    Acta Neuropathologica, 2010, 120 : 185 - 193
  • [35] Apolipoprotein E is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease
    Hesse, C
    Davidsson, P
    Lidstrom, AM
    Fredman, P
    Blennow, K
    JOURNAL OF NEUROCHEMISTRY, 1996, 66 : S3 - S3
  • [36] Analysis of the NOS3 polymorphism in Italian sporadic and familial Alzheimer's disease patients
    Cellini, E
    Tedde, A
    Nacmias, B
    Bagnoli, S
    Ciantelli, M
    Piacentini, S
    Sorbi, S
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S325 - S325
  • [37] Spontaneous and induced chromosome damage in somatic cells of sporadic and familial Alzheimer's disease patients
    Trippi, F
    Botto, N
    Scarpato, R
    Petrozzi, L
    Bonuccelli, U
    Latorraca, S
    Sorbi, S
    Migliore, L
    MUTAGENESIS, 2001, 16 (04) : 323 - 327
  • [38] Cathepsin D polymorphism in Italian sporadic and familial Alzheimer's disease
    Bagnoli, S
    Nacmias, B
    Tedde, A
    Guarnieri, BM
    Cellini, E
    Ciantelli, M
    Petruzzi, C
    Bartoli, A
    Ortenzi, L
    Serio, A
    Sorbi, S
    NEUROSCIENCE LETTERS, 2002, 328 (03) : 273 - 276
  • [39] Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease
    Madhurima Chatterjee
    Marta Del Campo
    Tjado H. J. Morrema
    Matthijs de Waal
    Wiesje M. van der Flier
    Jeroen J. M. Hoozemans
    Charlotte E. Teunissen
    Alzheimer's Research & Therapy, 10
  • [40] Auditory adaptation is differentially impaired in familial and sporadic Alzheimer's disease
    Tarkka, IM
    Lehtovirta, M
    Soininen, H
    Pääkkönen, A
    Karhu, J
    Partanen, J
    BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (01) : 45 - 49